Navigation Links
Debiopharm and EPFL Establish an Oncology Chair
Date:2/27/2008

LAUSANNE, Switzerland, February 27 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global independent biopharmaceutical development specialist focusing on serious medical conditions and particularly oncology, today announced the establishment of a Debiopharm oncology chair at the Ecole Polytechnique Federale de Lausanne (EPFL), focusing on Signal Transduction in Oncogenesis. Funded through a CHF 2.5 million endowment, the objective of the chair is to leverage the wide scope of ideas and inventions discovered by EPFL scientists and the global drug development expertise of Debiopharm. The synergy expected through this partnership will maximise the chances of bringing innovative drugs to patients.

The Debiopharm oncology chair will support the research work of Assistant Professor Dr Joerg Huelsken, of the EPFL Faculty of Life Sciences, which focuses on the role of the WNT signalling pathway in tumorigenesis and stem cell maintenance. Under the terms of the agreement, Debiopharm will also finance other potential collaborative research projects of mutual interest to both parties and will have the option to endow a second chair in Drug Design.

"The creation of this oncology chair will reinforce our involvement in local research," said Kamel Besseghir, CEO of Debiopharm S.A. "We are in close vicinity to the EPFL and have been collaborating on various projects over the past years. Our recently established office at the EPFL will contribute to build a critical mass in biomedical research in the Lake Geneva region, help us identify new projects and blend our ideas."

"The timing of our oncology chair at the EPFL could not have been better. The move of ISREC (Swiss Institute for Experimental Cancer Research) to the EPFL this year will increase their concentration of oncology expertise," added Rolland-Yves Mauvernay, President and Founder of Debiopharm Group."

"This partnership with Debiopharm is an example of how academic research and pharmac
'/>"/>

SOURCE Debiopharm Group
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. The Debiopharm Life Sciences Award Goes to Dr Nusser for his Outstanding Research in Neuroscience
2. Debiopharm Receives cGMP Certification for Quality Control of its Drug Products
3. Japanese Cancer Association and Debiopharm Honour Professors Minoru Toyota and Keiichi Nakayama With the 2007 JCA-Mauvernay Award
4. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
5. Cardinal Health Establishes $1 Million Grant Fund for Initiatives That Improve Quality, Safety of Patient Care
6. European Centre for Modern Drug Discovery Established in Hamburg
7. N.C. Takes Biofuels Leadership, Establishes New Endeavor With $5 Million State Appropriation
8. Edwards Lifesciences Grants UC Irvine $5 Million to Establish the Edwards Lifesciences Center for Advanced Cardiovascular Technology
9. KGI and Smith College Establish Leadership Forum for Women in Bioscience
10. Cellumen Establishes Collaboration in Breast Cancer Patient Stratification
11. Sigma-Aldrich and the Universite de Montreal Establish Collaboration for RNA Interference Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... BURNIE, Md. , Aug. 19, 2014 ... clinical research industry, recently announced the formation of the ... pleased to announce the addition of Dr. William ... Photo - http://photos.prnewswire.com/prnh/20140818/136957 The ... across a variety of therapeutic areas and set strategic ...
(Date:8/19/2014)... , Aug. 19, 2014   Synthetic Biologics, ... developing novel anti-infective biologic and drug programs targeting ... announced today that its novel C. difficile ... 54 th Interscience Conference on Antimicrobial Agents ... Washington D.C. Synthetic Biologics, ...
(Date:8/19/2014)... August 19, 2014 Sales Horizons, a ... its online sales skills training course to ... , MedTech clinical staff spend the majority of their ... standalone medical center, or physician practice – providing support ... why stop there? Sales Horizons believes clinical staff are ...
(Date:8/18/2014)... new therapy developed by researchers at the University ... and Columbia University Medical Center (CUMC) may help ... treatment. , The researchers demonstrated in a ... selectively inhibit blood vessel re-narrowing and simultaneously promote ... balloon catheter to open narrowed or blocked arteries. ...
Breaking Biology Technology:CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 2CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 3Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 2Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 3Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 4Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 2Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 3Selective therapy may improve artery repair after interventional cardiovascular procedures 2Selective therapy may improve artery repair after interventional cardiovascular procedures 3
... July 23 /PRNewswire-FirstCall/ - Roche,(SWX: ROG) and ARIUS ... have signed a definitive agreement for Roche to ... of approximately C$191 million. ARIUS is,the developer of ... and selects antibodies based on their functional,ability to ...
... ALTO, Calif., July 22 CV Therapeutics,Inc. (Nasdaq: ... quarter,financial results for 2008 after the market closes on ... call at 5:00 p.m. EDT,2:00 p.m. PDT, on the ... log on to the Company,s website at, http://www.cvt.com ...
... N.J., July 22 The Board of,Directors of BD ... declared a,quarterly dividend of 28.5 cents per common share. ... holders of record on September 9, 2008.,The indicated annual ... BD is a leading global medical technology company ...
Cached Biology Technology:Roche starts acquisition process of ARIUS to gain access to new screening platform for antibody therapeutics 2Roche starts acquisition process of ARIUS to gain access to new screening platform for antibody therapeutics 3Roche starts acquisition process of ARIUS to gain access to new screening platform for antibody therapeutics 4CV Therapeutics to Announce 2008 Second Quarter Financial Results on Thursday, July 31, 2008 2
(Date:8/19/2014)... German . ... a large amount of electricity is to be produced with ... to be stored during productive periods so that these fluctuations ... from adequate for the purpose. Science and industry are therefore ... battery systems that used to be too expensive or unsophisticated ...
(Date:8/19/2014)... lemur. It,s not an African Bush Baby or even a ... downright "cool" primate from Southeast Asia. , "It,s really not ... Brown, curator-in-charge at the University of Kansas, Biodiversity Institute. "A ... body; a long tail with a furry tuft at the ... a bit like the disks on the digits of tree ...
(Date:8/19/2014)... New measurements from fish purchased at retail seafood ... to which mislabeling can expose consumers to unexpectedly ... Fishery stock "substitutions"which falsely present a fish of ... originare the most dangerous mislabeling offense, according to ... scientists. , "Accurate labeling of seafood is essential ...
Breaking Biology News(10 mins):Asian inventions dominate energy storage systems 2Asian inventions dominate energy storage systems 3Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 2Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 3Seafood substitutions can expose consumers to unexpectedly high mercury 2Seafood substitutions can expose consumers to unexpectedly high mercury 3
... Canadian researcher working in the U.K. says doctors, authors ... claiming that hyperactivity as we understand it today has ... that notion wrong, it misleads patients, their parents and ... finishing up his PhD at the Centre for Medical ...
... embarrassing, but a new study suggests that it might ... interviewed more than three thousand men - all pairs ... - about the first time they had sex. Many ... from erectile dysfunction and premature ejaculation at their first ...
... for proposals, projects focus on either the development of ... and genomics. The Swiss National Science Foundation (SNSF) approved ... 47 research groups from both Swiss Federal Institutes of ... from the Universities of Basel, Lausanne, Geneva and Zurich. ...
Cached Biology News:History of hyperactivity off-base, says researcher 2Swiss Initiative in Systems Biology launches new projects 2
... This DuoSet ELISA Development kit contains the ... sandwich ELISAs to measure natural and recombinant ... and serum. Each kit contains sufficient materials ... plates, provided that the following conditions are ...
Blimp-1 (H-150)...
Mouse Galectin-1 Affinity Purified Polyclonal Ab...
PSGL-1 (215)...
Biology Products: